Dicronis GmbH develops microneedles for diagnostic and therapeutic purposes. The first product in our pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly-scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality-of-life of the patient and important savings for the healthcare system and society.